Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TSRA-196 in Alpha-1 Antitrypsin Deficiency
NCT07227207Phase 2Recruiting
- Sponsor
- Tessera Therapeutics
- Start
- Apr 2026
- Primary completion
- Mar 2029
- Modality
- Gene Editing, Gene Silencing, Lipid-based Nanoparticles
- Countries
- 4
01
Overview
A Phase 2 trial of TSRA-196 in alpha-1 antitrypsin deficiency (AATD), sponsored by Tessera Therapeutics. Started Apr 2026; status: recruiting.
02
Drugs
TSRA-196
03
Conditions
alpha-1 antitrypsin deficiency (AATD)
Beyond the preview
Go deeper on NCT07227207.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07227207.